Polaryx Therapeutics 定於9月10日虛擬舉行2026年度股東大會，股權登記日為7月27日

false
 0002075320
 
 
 
 
 
 
 
 0002075320
 
 
 2026-07-16
 2026-07-16
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934

 

Date of Report (Date of earliest event reported):
July 16, 2026

 

Polaryx Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 
 Nevada
  
 001-43080
  
 47-3393659

 
 (State or other jurisdiction
  
 (Commission
  
 (IRS Employer

 
 of incorporation)
  
 File Number)
  
 Identification No.)

 
 

South
Tower,140 E Ridgewood Avenue, Suite
415

Paramus, NJ 07652

(Address of principal executive offices) (Zip Code)

 

(201) 940-7236 

Registrant’s telephone number, including
area code

 

Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 
 ☐
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
  
  

 
 ☐
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
  
  

 
 ☐
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
  
  

 
 ☐
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Securities registered pursuant to Section 12(b)
of the Act:

 

 
 Title of each class
  
 Trading Symbol(s)
  
 Name of each exchange on which registered

 
 Common Stock, par value $0.0001 per share
  
 PLYX
  
 The Nasdaq Capital Market

 
 

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   

 

 

 

Item 5.08. Shareholder Director Nominations.

 

To the extent applicable, the information in Item
8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08.

 

Item 8.01. Other Events.

 

On July 16, 2026, the Board of Directors (the
“Board”) of Polaryx Therapeutics, Inc. (the “Company”) determined that the Company’s 2026 Annual Meeting of
Stockholders (the “Annual Meeting”) will be held virtually on September 10, 2026. The Company will provide additional details
regarding the time and matters to be voted on at the Annual Meeting in the Company’s proxy statement for the Annual Meeting to be
filed with the U.S. Securities and Exchange Commission (the “SEC”) prior to the Annual Meeting. Stockholders of record of
the Company’s common stock at the close of business on July 27, 2026 will be entitled to notice of, and to vote at, the Annual Meeting
and any adjournments or postponements thereof. The Company, however, reserves the right to change the record date, meeting date, and meeting
location prior to the Annual Meeting.

 

Because the Company did not hold an annual meeting
of stockholders during 2025, stockholders of the Company who wish to have a proposal considered for inclusion in the Company’s proxy
materials for the Annual Meeting pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended,
(the “Exchange Act”) must ensure that such proposal is delivered to or mailed to and received by the Company to the attention
of Alex Yang at South Tower,140 E Ridgewood Avenue, Suite 415, Paramus, NJ 07652 on or before the close of business on July 27, 2026,
which date the Company has determined is a reasonable time before it expects to begin to print and distribute its proxy materials.

 

In addition to complying with the July 27, 2026
deadline, stockholder director nominations and stockholder proposals intended to be considered for inclusion in the Company’s proxy
materials for the Annual Meeting must also comply with all applicable SEC rules, including Rule 14a-8 under the Exchange Act, Nevada corporate
law and the Company’s Amended and Restated Bylaws. Any director nominations and stockholder proposals received after July 27, 2026
will be considered untimely and will not be considered for inclusion in the proxy materials for the Annual Meeting nor
will it be considered at the Annual Meeting.

 

 1

 

 

 

SIGNATURES

 

Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.

 

 
  
 Polaryx Therapeutics, Inc.

 
  
  

 
  
 /s/ Alex Yang

 
  
 Alex Yang

 
  
 Chief Executive Officer

 
  
  

 
 July 17, 2026
  

 
 

 2